Tissue-type plasminogen activator (tPA) circulating in plasma exists in free forms as well as in tPA-inhibitor complexes. The underlying biochemical mechanism governing coagulation and fibrinolysis involves a controlled cascade of proteolytic reactions characterized by the conversion of serine protease zymogens to enzymes. Depending upon the initiating stimulus, the physiological outcome of these reactions is blood clot formation/dissolution. The relative concentrations of serine protease zymogen, enzyme, or enzyme-inhibitor complex in circulation will vary in accord with the state of vascular damage. Many conventional antigen-based clotting factor-specific immunoassays do not distinguish between zymogen and enzyme. Applications: Suitable for use in FLISA and Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1-5ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: Store product at 4C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20C. Aliquots are stable at -20C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Note: Applications are based on unconjugated antibody.
Reinheit:
Purified by Protein A affinity chromatography.
Formulierung:
Supplied as a liquid in PBS, pH 7.2. No preservative added. No stabilizing proteins added. Labeled with Fluorescein isothiocyanate (FITC).
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
